Yr Athro Simon Ward

: Siarad Cymraeg
: Ar gael fel goruchwyliwr ôl-raddedig

Timau a rolau for Simon Ward

Athro
Yr Ysgol Meddygaeth

Mae'r Athro Simon Ward yn Athro Darganfod Cyffuriau Trosiadol Sêr Cymru, a Chyfarwyddwr y Sefydliad Darganfod Meddyginiaethau ym Mhrifysgol Caerdydd. Nod y sefydliad, sy'n fuddsoddiad pwysig mewn gwyddoniaeth darganfod cyffuriau, yw cyfieithu dealltwriaeth newydd o fecanweithiau clefydau yng Nghaerdydd, Cymru a rhyngwladol i ddatblygu dulliau therapiwtig newydd ar gyfer cleifion sydd angen gwell opsiynau triniaeth.

Mae'r Athro Simon Ward yn arbenigwr blaenllaw byd-eang mewn cemeg feddyginiaethol, darganfod cyffuriau a datblygu cyffuriau ac mae wedi gyrru sawl prosiect o gysyniad i astudiaethau clinigol canol cam ar gyfer ystod o glefydau. Mae ganddo brofiad helaeth ar draws sectorau o gwmnïau fferyllol mawr, cwmnïau biotechnoleg, elusennau a'r byd academaidd, yn ogystal â phrofiad arbenigol o ddarganfod a datblygu cyffuriau ar gyfer cleifion ag anhwylderau niwrolegol a seiciatrig ac yn erbyn canser. Mae ganddo brofiad sylweddol o fargeinion trwyddedu llwyddiannus, diwydrwydd dyladwy, ymgyfreitha patent a chreu cytundebau masnachol.

Date
Type

2012

Andreotti, D. et al., 2012. Piperazine derivatives as cav2.2 calcium channel blockers. WO2012098400A1[Patent]
Bertheleme, N. et al., 2012. Tetrazole compounds as calcium channel blockers. WO2012004604A1[Patent]

2011

Cowley, P. , Hales, N. and Ward, S. 2011. Trends in medicinal chemistry. Presented at: The Society For Medicines Resarch Symposiun NHLI, London, UK 9 December 2010. Vol. 36.Vol. 7. Prous Science. , pp.543-549. (10.1358/dof.2011.036.07.1622065)
Davenport, R. , Armour, R. and Ward, S. 2011. Trends in pain research. Presented at: The Society for Medicines Research Pain Meeting Girton College, Cambridge, UK 24 March 2011. Vol. 36.Vol. 12. Prous Science. , pp.943-948. (10.1358/dof.2011.036.12.1738058)
Ward, S. et al. 2011. Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators. Journal of Medicinal Chemistry 54 (1), pp.78-94. (10.1021/jm100679e)

2010

Leslie, C. P. et al., 2010. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT1A/B/DReceptor antagonist. Journal of Medicinal Chemistry 53 (23), pp.8228-8240. (10.1021/jm100714c)
Thewlis, K. M. et al., 2010. N-Substituted pyrrolidines and tetrahydrofurans as novel AMPAR positive modulators. Bioorganic & Medicinal Chemistry Letters 20 (23), pp.7116-7119. (10.1016/j.bmcl.2010.09.062)
Ward, S. et al. 2010. Discovery of N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulator. Journal of Medicinal Chemistry 53 (15), pp.5801-5812. (10.1021/jm1005429)
Bradley, D. M. et al., 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010066658A1[Patent]
Coulton, S. , Gilpin, M. and Ward, S. 2010. N- inden- 2 -yl- isopropylsulfonamides as ampa receptor potentiators. WO2010057865A1[Patent]
Ward, S. , Bax, B. D. and Harries, M. 2010. Challenges for and current status of research into positive modulators of AMPA receptors. British Journal of Pharmacology 160 (2), pp.181-190. (10.1111/j.1476-5381.2010.00726.x)
Ward, S. and Betheleme, N. 2010. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2010037760[Patent]
Heer, J. P. , Norton, D. and Ward, S. 2010. Pyrazolo [1, 5-a] pyrimidine derivatives. WO2010007074A1[Patent]
Ward, S. and Harries, M. 2010. Recent advances in the discovery of selective AMPA receptor positive allosteric modulators. Current Medicinal Chemistry 17 (30), pp.3503-3513. (10.2174/092986710792927840)
Ward, S. and Watson, J. M. 2010. Recent advances in the discovery of selective and non-selective 5-HT1D receptor ligands. Current Topics in Medicinal Chemistry 10 (5), pp.479-492. (10.2174/156802610791111533)

2009

Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092712A1[Patent]
Thewlis, K. M. and Ward, S. 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009092713A1[Patent]
Bertheleme, N. et al., 2009. Compounds which potentiate the ampa receptor and uses thereof in medicine. WO2009080637A1[Patent]
Chan, W. N. et al., 2009. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2009053448A1[Patent]
Chan, W. N. , Thewlis, K. M. and Ward, S. 2009. Thiazoles which potentiate ampa receptor and medicinal uses thereof. WO2009053449A1[Patent]
Alderton, W. , Karran, E. and Ward, S. 2009. Current and future perspectives in psychiatric drug discovery. Presented at: Society for Medicines Research Symposium GlaxoSmithKline, Harlow, U.K 12 March 2009. Vol. 22.Vol. 6. Thomson Reuters. , pp.360-364. (10.1358/dnp.2009.22.6.1380328)

2008

Ward, S. et al. 2008. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II. Biorganic and Medicinal Chemistry Letters 19 (2), pp.428-432. (10.1016/j.bmcl.2008.11.052)
Bartheleme, N. et al., 2008. Compounds which potentiate AMPA receptor and uses thereof in medicine. WO2008113795[Patent]
Bradley, D. et al., 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008110566A1[Patent]
Bradley, D. , Thewlis, K. and Ward, S. 2008. Compounds which potentiate ampa receptor and uses therof in medicine. WO2008148832A1[Patent]
Bradley, D. et al., 2008. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2008053031A1[Patent]
Ward, S. et al. 2008. Discovery of potent, orally bioavailable, selective 5-HT1A/B/DReceptor antagonists. Journal of Medicinal Chemistry 51 (10), pp.2887-2890. (10.1021/jm8001444)
Gillespie, R. J. et al., 2008. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Biorganic and Medicinal Chemistry Letters 18 (9), pp.2916-2919. (10.1016/j.bmcl.2008.03.075)

2007

Bradley, D. et al., 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007122241A1[Patent]
Bradley, D. et al., 2007. Compounds which potentiate ampa receptor and uses thereof in medicine. WO2007107539A1[Patent]
Andreotti, D. and Ward, S. 2007. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2007090841A1[Patent]
Thewlis, K. and Ward, S. 2007. 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia. WO2007090840A1[Patent]
Ward, S. et al. 2007. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands. Biorganic and Medicinal Chemistry Letters 17 (18), pp.5214-5217. (10.1016/j.bmcl.2007.06.078)
Ahmad, N. M. et al., 2007. Synthesis of polyprenylated acylphloroglucinols using bridgehead lithiation: the total synthesis of racemic clusianone and a formal synthesis of racemic garsubellin A. The Journal of Organic Chemistry 72 (13), pp.4803-4815. (10.1021/jo070388h)
Ahmad, N. M. et al., 2007. Synthetic studies towards garsubellin A: synthesis of model systems and potential mimics by regioselective lithiation of bicyclo[3.3.1]nonane-2,4,9-trione derivatives from catechinic acid. Organic & Biomolecular Chemistry 5 (12), pp.1924-1934. (10.1039/b704311b)

2006

Craig, D. , Hyland, C. J. T. and Ward, S. 2006. Stereoselective synthesis of (-)-trachelanthamidine (IV) via palladium-catalyzed intramolecular allylation.. Chem Inform 37 (50)(10.1002/chin.200650213)
Lovell, P. J. et al., 2006. 3,4-Dihydro-2H-benzoxazinones as dual-acting 5-HT1A receptor antagonists and serotonin reuptake inhibitors. Bioorganic and Medicinal Chemistry Letters 17 (4), pp.1033-1036. (10.1016/j.bmcl.2006.11.031)
Bradley, D. et al., 2006. Acylated piperidihes as glycine transporter inhibitors. WO2006094842[Patent]
Andreotti, D. et al., 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006087169A1[Patent]
Bradley, D. et al., 2006. Glycine transport inhibitors. WO2006067423A1[Patent]
Bradley, D. et al., 2006. Glycine transport inhibitors. WO2006067417A1[Patent]
Bradley, D. M. , Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015828[Patent]
Thewlis, K. M. and Ward, S. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO 2006015827[Patent]
Ward, S. and Thewlis, K. M. 2006. Compounds which potentiate glutamate receptor and uses thereof in medicine. WO2006015829[Patent]

2005

Craig, D. , Hyland, C. J. T. and Ward, S. 2005. Stereoselective γ-lactam synthesis via palladium-catalysed intramolecular allylation. Chemical Communications- Royal Society of Chemistry (27), pp.3439-3441. (10.1039/b504731e)
Ward, S. et al. 2005. Discovery of the first potent, selective 5-Hydroxytryptamine1D receptor antagonist [Letter]. Journal of Medicinal Chemistry 48 (10), pp.3478-3480. (10.1021/jm049039v)
Bergauer, M. et al., 2005. Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors. WO 2005014552[Patent]

2004

Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use. WO 2004099198[Patent]
Vong, A. and Ward, S. E. 2004. Benzoxazinone derivatives, their preparation and use. WO2004099196A1[Patent]

2003

Flynn, S. T. et al., 2003. Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors. WO2003068236A1[Patent]
Harrington, F. P. , Smith, P. W. and Ward, S. E. 2003. Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy. WO2003068772A1[Patent]
Smith, P. W. et al., 2003. Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders. WO2003068760A2[Patent]
Ward, S. E. 2003. Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors. WO2003068771A1[Patent]

2000

Gillespie, R. J. et al., 2000. 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission. WO2000044371A1[Patent]
Gillespie, R. J. et al., 2000. 4-quinolinemethanol derivatives as purine receptor antagonists (i). WO2000013681A2[Patent]

1999

Gillespie, R. J. , Snape, M. F. and Ward, S. E. 1999. 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission. WO1999031051A1[Patent]

1998

Adger, B. M. et al., 1998. A novel synthesis of tert-leucine via a Leuckart type reaction. Tetrahedron Letters 38 (12), pp.2153-2154. (10.1016/S0040-4039(97)00269-4)

1997

Ward, S. , Holmes, A. B. and McCague, R. 1997. Total synthesis of carbocyclic nikkomycin C. Chemical Communications- Royal Society of Chemistry (21), pp.2085-2086. (10.1039/a705825j)

1993

Congreve, M. S. et al., 1993. Selective cleavage of benzyl ethers [Letter]. Synlett 1993 (09), pp.663-664. (10.1055/s-1993-22563)

Davis, A. M. and Ward, S. null. The handbook of medicinal chemistry principles and practice. Cambridge: Royal Society of Chemistry.
Ward, S. null. AMPA receptor positive allosteric modulators a case history.. In: Cox, B. and Gosling, M. eds. Ion Channel Drug Discovery. Vol. 39, RSC Drug Discovery Series Vol. 39.Cambridge: Royal Society of Chemistry. , pp.105-134.
Ward, S. null. Discovery and clinical data for a novel AMPA receptor positive modulator. In: Rankovic, Z. , Hargreaves, R. and Bingham, M. eds. Drug Discovery for Psychiatric Disorders. RSC Drug Discovery Series Vol. 28.Cambridge: Royal Society of Chemistry. , pp.99-122. (10.1039/9781849734943)
Ward, S. null. DNA damage repair pathways and synthetic lethality. In: Lackey, K. and Roth, B. eds. Medicinal Chemistry Approaches to Personalized Medicine. Vol. 59, Wiley-Blackwell. , pp.183-210.
Ward, S. null. Neurotransmitters and other non-opiate central mechanisms. In: Allerton, C. ed. Pain Therapeutics: Current and Future Paradigms. RSC Drug Discovery Series Vol. 35.Cambridge: Royal Society of Chemistry. , pp.171-196.

Mae'r Athro Ward yn Ymchwilydd ar sawl dyfarniad grant, gan gynnwys y dyfarniadau canlynol:

Prosiectau Byw	Cyllidwr	Gwerth
KAT2A PROTACs sy'n targedu gwahaniaethu ffrwydrau a bôn-gelloedd lewcemig ar gyfer trin Lewcemia Myeloid Acíwt [PI]	Cartref	>£1M
Gwella swyddogaeth llinyn y cefn GlyRa3 fel dull newydd o drin poen [coI]	Cartref	>£1M
Moleciwlau offeryn ar gyfer ataliad NEAT1 [PI]	Coleg Cymraeg Cenedlaethol	Ysgoloriaeth PhD
Chimeras Targedu Protein (PROTACs) ar gyfer treiddiad CNS [PI]	Fferyllol Janssen	Ysgoloriaeth PhD
Astudiaethau clinigol Cam 1 ar gyfer MDI-478: Modiwlydd allosterig positif derbynnydd AMPA ar gyfer trin nam gwybyddol sy'n gysylltiedig â sgitsoffrenia [PI]	Ymddiriedolaeth Wellcome	>£6M
Modulators allosterig o dderbynyddion delta-GABAA allsynaptig ar gyfer trin iselder ôl-enedigol [coI]	Cartref	>£5M
Dylunio a datblygu modulators derbynnydd AMPA gyda phroffil diogelwch llawer gwell fel cyffuriau newydd ar gyfer trin y camweithrediad gwybyddol sy'n gysylltiedig â sgitsoffrenia ac anhwylderau CNS eraill [PI]	Ymddiriedolaeth Wellcome	>£4M
Prawf Cysyniad ar gyfer a5-GABAAR PAMs wrth drin seicosis [coI]	Ymddiriedolaeth Wellcome	>£500k
Datblygu moleciwlau bach fel strategaeth amnewid niwrosteroidau ar gyfer trin seicosis ôl-enedigol [coI]	Ymddiriedolaeth Wellcome	>£500k
Targedu proteinau Prion gyda PROTACs [PI]	Coleg Cymraeg Cenedlaethol	Ysgoloriaeth PhD
Atal ceramidase asid i drin anhwylderau storio lysosomaidd lluosog [coI]	Clefyd Prin Harrington	£100k
Modiwlyddion Derbynnydd α5-GABAA ar gyfer Trin Nam Gwybyddol sy'n Gysylltiedig â Chlefyd Huntington [coI]	Ymddiriedolaeth Wellcome	>£3M

Mae gan yr Athro Ward MA mewn Gwyddorau Naturiol a PhD mewn cemeg organig synthetig o Brifysgol Caergrawnt, y Deyrnas Unedig. Mae ganddo brofiad eang o ddarganfod cyffuriau mewn cwmnïau fferyllol, biotechnoleg ac academaidd mawr (GlaxoSmithKline, BioCrea GmbH, Knoll Pharmaceuticals, Vernalis, Ceirowyddoniaeth, Prifysgol Sussex, Prifysgol Caerdydd) a phrofiad arbenigol o ddatblygu meddyginiaethau newydd ar gyfer cleifion â salwch niwrolegol a seiciatrig ac yn erbyn canser. Yn 2010, ar ôl gyrfa ymchwil mewn diwydiant, cyfunodd yr Athro Ward rolau mewn cwmnïau biotechnoleg gyda rôl academaidd, sefydlu un o brif grwpiau darganfod cyffuriau prifysgolion y DU gan sicrhau dros £50 miliwn o gyllid academaidd gan gyllidwyr elusennol, y llywodraeth a diwydiannol.

Yn ogystal â rolau ymgynghori allanol a biotechnoleg, mae'r Athro Ward hefyd:

Aelod o'r Pwyllgor Cynghori Gwyddonol Arbenigol, Medicines for Malaria Venture
Aelod o'r Bwrdd Cynghori Gwyddonol, Sefydliad Therapiwteg Canser, Bradford, y DU
Bwrdd Cynghori, Enterprise Therapeutics
Aelod o Fwrdd Rheoli Arloesi Caerdydd, y DU
Aelod o'r Bwrdd Cynghori ar gyfer cyfnodolion Bioorganic and Medicinal Chemistry & Bioorganic and Medicinal Chemistry Letters, Elsevier a Medicinal Chemistry Letters, American Chemical Society
Cadeirydd Cwrs Hyfforddi Preswyl Cemeg Feddyginiaethol Cymdeithas Frenhinol Cemeg
Cyd-olygydd The Handbook of Medicinal Chemistry: Principles and Practice, Cymdeithas Frenhinol Cemeg 2015 a 2023
Cyd-brif olygydd Cemeg Feddyginiaethol Gynhwysfawr Cyfrol IV, Elsevier 2025
Aelod o Sefydliad Panel Arbenigwyr Buddsoddi Ymchwil mewn Technolegau Iechyd Byd-eang (RIGHT), Korea

Mae'r Athro Ward yn Gymrawd o'r Gymdeithas Cemeg Frenhinol, yn Gemegydd Siartredig, ac yn Wyddonydd Siartredig (FRSC CChem CSci).